SANUWAVE Health, Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
SANUWAVE reported preliminary Q2 2026 revenue of $9.6–$9.8 million, exceeding the revised guidance range of $8.5–$9.5 million issued June 16, 2026. Revenue declined 3–5% year-over-year from $10.1 million in Q2 2025, but consumable applicator sales set all-time records in both unit and revenue volume. Capital equipment sales faced headwinds from customer financial stress and secondary-market competition (used Ultramist systems), which the company is addressing through trade-in programs and support for new users.
Why this rating
Beat guidance is positive, but YoY decline and structural headwinds offset gains. Modest dollar scale (~$9.7M quarterly) is ~17% annualized of $233M market cap—material but not transformative.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.